🇺🇸 FDA
Patent

US 11225506

Cell penetrating peptides and methods of making and using thereof

granted A61KA61K38/05A61K38/12

Quick answer

US patent 11225506 (Cell penetrating peptides and methods of making and using thereof) held by Entrada Therapeutics, Inc. expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Entrada Therapeutics, Inc.
Grant date
Tue Jan 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
41
CPC classes
A61K, A61K38/05, A61K38/12, A61K38/465, A61K47/64